Navigation Links
Soligenix Announces Pricing of Public Offering of Common Stock and Warrants
Date:6/21/2013

PRINCETON, N.J., June 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today the pricing of a registered public offering of shares of common stock and warrants to purchase common stock.

In connection with the public offering, the Company has entered into definitive agreements with institutional investors and certain members of the Company's management and Board of Directors to sell approximately $7.0 million of the Company's securities, consisting of an aggregate of approximately 6.6 million shares of common stock at a price per share of $1.05 and 5-year warrants to purchase up to approximately 5.0 million shares of common stock with an exercise price of $1.65 per share.

Institutional investors in the offering include, among others, an affiliated fund of Third Security, LLC ("Third Security"), a venture capital firm founded by R.J. Kirk.  In connection with Third Security's investment in the Company, the Company intends to appoint a Third Security designee to the Board of Soligenix.

The Company plans to use the net proceeds from the offering to further develop its product candidates and for general working capital purposes.

Soligenix's two lead product candidates include a proprietary formulation of oral BDP (beclomethasone 17,21-dipropionate) for pediatric Crohn's disease (SGX203), which is currently in a Phase 1 clinical trial, and a novel innate defense regulator (IDR) technology for the treatment of oral Mucositis (SGX942) for which the Company plans to initiate a Phase 2 clinical trial in the second half of 2013.

Maxim Group LLC served as placement agent for the offering.

The securities described above were offered
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
2. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
3. Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
4. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
5. Soligenix to Present at World Vaccine Congress & Expo
6. Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
7. Soligenix to Present at 15th Annual BIO CEO & Investor Conference
8. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
9. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
10. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
11. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Cepheid (NASDAQ: CPHD ) today announced ... and invited investors to participate via webcast. ... York, NY Wednesday, August 13, 2014 at 9.10 ... New York, NY Thursday, September 4, ... Live Webcasts To access the live webcasts for these events, ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
(Date:7/31/2014)... July 31, 2014  UBM Medica US announces that ... community for oncologists, presents exclusive slide shows dealing with ... to quality cancer care. Cancer Network, ... , offers news, blogs, and podcasts about the latest ... cancer care: , End-of-life care is challenging ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... TEL AVIV, Israel, December 20, 2011 During ... Board of Governors of the Israel-U.S. Binational Industrial Research ... for nine new projects between Israeli and American companies. In ... private sector funding, boosting the total value of all projects ...
...  The National Urban League (NUL) and the League of United ... to resume negotiations and come to an agreement with Walgreens ... millions of Americans, especially in diverse and underserved communities, stand ... In an open letter to Express Scripts, ...
Cached Medicine Technology:BIRD - Israel-US Binational Industrial R&D Foundation to Invest $8.1 Million in Nine new Projects 2BIRD - Israel-US Binational Industrial R&D Foundation to Invest $8.1 Million in Nine new Projects 3The National Urban League and League of United Latin American Citizens Urge Express Scripts to Reach Agreement with Walgreens 2The National Urban League and League of United Latin American Citizens Urge Express Scripts to Reach Agreement with Walgreens 3
(Date:8/1/2014)... August 01, 2014 The "Antimicrobial ... such as Zinc Oxide, Titanium Dioxide, and Zinc ... & Construction, Food & Beverages, Textiles, and others), ... - Global Trends and Forecasts to 2018" analyzes ... drivers, opportunities, and trends in the diverse geographical ...
(Date:8/1/2014)... parents worry about their children choking on small objects or ... Such was the case for 15-month-old Landon Jones who started ... "At the time, Landon had a cold so it ... illness or choking," recalled his mother, Ula Jones. But, ... his windpipe and had to be removed via surgery. Landon ...
(Date:8/1/2014)... 01, 2014 For years, proponents have ... recent study conducted by the Ohio State ... far behind in terms of their health and development, ... what’s best for their baby. So does this new ... Dr. Steven Shapiro , chair of Pediatrics at Abington ...
(Date:8/1/2014)... (BRONX, NY) Scientists at Albert Einstein ... that bacteria that aid in digestion help keep the ... journal Immunity , could yield new therapies for ... other disorders. , The research involved the intestinal microbiome, ... these microorganisms in promoting or preventing disease is a ...
(Date:8/1/2014)... today’s age, traditional learning methods are futile in helping ... need to be revamped, so that the necessary subject ... age of the internet, online learning resources act as ... systems help in the planning, implementation, and assessment of ... proving to be very useful and this trend is ...
Breaking Medicine News(10 mins):Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 4
... France's best-loved cheeses is in question after the two biggest ... untreated "raw" milk -- stopped production, citing health risks ... Lactalis and the Isigny Cooperative -- who together supplied 90 ... northwest region of Normandy -- have switched to using treated ...
... billion dollars) over the next eight years to the global ... to be published Thursday. ,Heidemarie Wieczorek-Zeul told ... to send a message to other member states during the ... Heiligendamm. ,"My appeal goes out to the other ...
... Hong Kong teenagers vibrates to the latest dance hit as a ... ,"Scream louder if you want more," a DJ shouts ... low-cut jeans throws his female partner onto his lap in a ... typical Friday night, but while many of the clubbers hail from ...
... Finnish Research study has found that exposure even a small ... serious and harmful impact on the cardiovascular system of a ... smoke can harm the childs arteries. ,Instead of relying ... the Finnish researchers used high-resolution ultrasound to check brachial artery ...
... old resident in New York, drank Boost Plus, a vitamin enriched ... ,When he woke up the next day, he had ... for medical advice and for treatment of the condition called severe ... is persistent, painful erection of the penis. Recurrent or severe episodes ...
... that the prison population in England and Wales reached a ... there were fewer than 300 cells available for new inmates. ... to house prisoners in some areas of the country. ... the BMAs Civil and Public Services Committee said: ...
Cached Medicine News:Health News:Fate of France's Cheeses in Doubt as Producers Cite Health Risks 2Health News:Fate of France's Cheeses in Doubt as Producers Cite Health Risks 3Health News:Drugs Lure Hong Kong Youth Across China Border 2Health News:Drugs Lure Hong Kong Youth Across China Border 3Health News:Prison Healthcare Under Strain as Overcrowding Crisis Worsens, Warns BMA 2
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
Intended for the quantitative determination of iron in serum. Reaction: Endpoint. Wavelength: 595 nm. Linearity: 500 g/dL (89.5 mol/L). Two vials, liquid reagents....
HDL Cholesterol, liquid....
For the quantitative determination of high density lipoprotein (HDL) in human serum....
Medicine Products: